Europe Digital PCR and qPCR Market Size, Share, Trends & Growth Forecast Report By Product, Technology, Application, End User and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, From (2026 to 2034)
The digital PCR and real-time PCR (qPCR) market in Europe was valued at USD 1,149 million in 2025 and is expected to grow at a CAGR of 8.9% from 2026 to 2034. The European market is anticipated to be worth USD 2,475 million by 2034 from USD 1,252 million in 2026.

The growing use of real-time PCR and digital PCR for identifying genetic disorders and other infectious diseases like tuberculosis, malaria, and others is a significant factor driving the digital PCR and qPCR market in Europe. Furthermore, the further expansion of the European market is boosted by the increased focus of government and business entities on developing unique and creative digital PCR and qPCR products. Furthermore, the emergence of innovative and improved genomic analysis tools across the region is another significant factor promoting the digital PCR and qPCR market expansion in Europe. In addition, the high efficiency of digital PCR and qPCR equipment for estimating disease-causing microorganisms and diagnostics analysis is fueling the growth of the digital PCR and qPCR market in Europe.
Increasing healthcare spending in emerging economies and other developed and developing countries around the world, as a result of an increase in the incidence of genetic disorders and other chronic diseases like cancer, as well as technological advancements, is expected to create lucrative opportunities for market players in the region over the forecast period. The advantages of digital PCR over traditional PCR, such as accuracy, sensitivity, and flexibility, are expected to drive the European digital PCR and qPCR market forward throughout the forecast period. Furthermore, increasing uses of qPCR consumables and reagents and other clinical applications are expected to provide additional growth prospects for this market.
The growth of the digital PCR and qPCR market in the European region is forecasted to be hampered by the technical problems, the high initial cost of dPCR and qPCR, the necessity for large-scale capital investments to create advanced equipment. In addition, the adoption rate of digital PCR and qPCR in Europe is also constrained by technical difficulties connected to PCR, another key factor impeding the market's growth.
| REPORT METRIC | DETAILS |
| Market Size Available | 2025 to 2034 |
| Base Year | 2025 |
| Forecast Period | 2026 to 2034 |
| Segments Covered | By Product, Technology, Application, End User, and Region. |
| Various Analyses Covered | Global, Regional and Country-Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
| Countries Covered | UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic, and the Rest of Europe |
| Market Leaders Profiled | Thermo Fisher Scientific Inc., F Hoffman-La Roche Ltd., Bio-Rad Laboratories, Qiagen N.V., Taraka Bio Inc., Affymetrix Inc., Agilent Technologies Inc., Fluidigm Corporation, Danaher Corporation, and Becton & Dickson Company. |
Over the forecast period, Europe is predicted to be the second-largest region for dPCR and qPCR across the globe. The wide range of applications of qPCR and dPCR technologies in human genetic testing and forensic sciences is one of the factors driving the region's market growth. Because of the rising frequency of infectious and chronic diseases, as well as increased R&D initiatives to develop breakthrough genomic techniques such as qPCR and dPCR, emerging markets are likely to offer considerable growth potential. The expansion of healthcare infrastructure increased healthcare expenditure, and lower procedural costs for qPCR and dPCR-based illness diagnostics are all driving these markets forward. The development of healthcare infrastructure in emerging countries is accompanied by rapid upgrading of healthcare facilities. As a result, clinical diagnostic procedures are in greater demand among diagnostic laboratories, resulting in more sales of clinical qPCR and dPCR products.
The UK is expected to dominate the European market for Digital PCR and Quantitative PCR during the forecast period. There is strong growth in the market due to key factors such as the presence of key players, high incidence of chronic diseases in the region, and established healthcare infrastructure.
Thermo Fisher Scientific Inc., F Hoffman-La Roche Ltd., Bio-Rad Laboratories, Qiagen N.V., Taraka Bio Inc., Affymetrix Inc., Agilent Technologies Inc., Fluidigm Corporation, Danaher Corporation, and Becton & Dickson Company are a few of the noteworthy companies operating in the European Digital PCR and qPCR Market.
This Europe digital PCR and real-time PCR (qPCR) market research report is segmented and sub-segmented into the following categories.
By Product
By Technology
By Application
By End User
By Country
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from
$ 2000
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: sales@marketdataforecast.com
Reports By Region